계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
NovoCure
company
About
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
- 501 - 1000
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $150M
- Industries
- Health Care,Medical Device
- Founded date
- Jan 1, 2000
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$150M
NovoCure has raised a total of
$150M
in funding over 2 rounds. Their latest funding was raised on
Nov 9, 2020 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 9, 2020 | Post-IPO Debt | $150M | 1 |
JP Morgan Chase
|
— | Detail |
| Sep 28, 2009 | Series Unknown | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
NovoCure is funded by 2 investors.
JP Morgan Chase
and Pfizer
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
JP Morgan Chase
|
Yes | Post-IPO Debt |
Pfizer
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
